Testing a new drug combo before liver surgery for colorectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial is for people with colorectal cancer that has spread to the liver. It tests whether adding a new drug (sotevtamab) to standard chemotherapy (FOLFOX) before surgery can help shrink tumors and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- Your colorectal cancer has spread to the liver, and the liver tumors can be removed with surgery.
- You have not had chemotherapy for cancer that has already spread.
- You have at least one tumor that can be measured on scans.
- You are willing to have a biopsy of a liver tumor before treatment.
- You are able to walk and take care of yourself (ECOG score of 0-2).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two chemotherapy drugs (FTD and tipiracil), a targeted therapy (bevacizumab), and a radiation treatment (radioembolization) for people with colorectal cancer that has spread mainly to the liver and hasn't responded to other treatments. The goal is to see if this combination can shrink tumors and help control the cancer.
This trial tests a new combination of drugs for people with colorectal cancer that has spread to the liver and cannot be removed by surgery. It aims to shrink or control these liver tumors.
This trial is testing a combination of a new immunotherapy drug (QL1706) with chemotherapy and either cetuximab or bevacizumab for people with colorectal cancer that has spread to the liver and can potentially be removed by surgery. The goal is to shrink the tumors before surgery, making them easier to remove.
This trial tests whether adding two targeted drugs (serplulimab and bevacizumab) to standard chemotherapy before surgery can improve outcomes for people with colorectal cancer that has spread to the liver. It is for those whose cancer has certain genetic features and is considered resectable.
This trial tests a combination treatment that uses heat or cold (ablation) to destroy liver tumors along with medicines that boost your immune system to fight cancer. It is for people whose colorectal cancer has spread to the liver and who could not have surgery, or whose first treatment stopped working.
This study tests a new drug (ivosimab, an immunotherapy) combined with chemotherapy given before surgery for colorectal cancer that has spread to the liver. The goal is to shrink the liver tumors to make surgery easier and improve the chance of removing all cancer.
Hear when a new Metastatic Colorectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.